Fig. 1 · Structure

Documents & Downloads

Methazolastone

Cat. No. A10575 CAS 85622-93-1

DNA damage inducer

Methazolastone is a DNA damage inducer.

In Stock

Publications for Methazolastone

3 publications citing this product

  1. Katarzyna Kucwaj-Brysz, .et al. , Sci Rep, 2026, Mar 24;16(1):14883 PMID: 41876621
  2. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  3. VJ Herbener, .et al. , Biomedicines, 2020, Jun 4;8(6):E151 PMID: 32512726

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
DNA replication (L-1210, L-1210/BCNU cells)

Cellular Effect

Cell Line Activity Value Description Reference
A 172 IC50 > 40 μM Cytotoxicity against human A 172 cells assessed as cell viability measured after 96 hrs by XTT assay [PMID: 34507011]
A 172 IC50 6.5 x 10 Antiproliferative activity against human A172 cells after 5 days by MTT assay [PMID: 22608389]
A2058 IC50 35.5 μM Chemosensitization of human A2058 cells after 5 days by MTT assay [PMID: 23895620]
A2780 IC50 > 250 μM Chemosensitization of human A2780 cells after 5 days by MTT assay [PMID: 23895620]
A2780 IC50 > 250 μM Cytotoxicity against human A2780 cells after 5 days by MTT assay in presence of 10 uM MGMT inactivator Patrin2 [PMID: 24900418]
A2780 IC50 368 μM Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2 [PMID: 11063605]
A2780 IC50 525 μM Potentiation of growth inhibition of A2780 by compound alone in experiment 1 [PMID: 11063605]
A2780 IC50 8.5 μM Chemosensitization of human A2780 cells after 5 days by MTT assay in presence of MGMT inactivator PaTrin2 [PMID: 23895620]
A-375 IC50 > 75 μM Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay [PMID: 34795855]
A-431 IC50 366 μM Antiproliferative activity in human A431 Cells after 72 hrs by SRB assay [PMID: 28494256]
A549 IC50 > 250 μM Cytotoxicity against human A549 cells after 5 days by MTT assay [PMID: 24900418]
Astrocyte IC50 > 1 mM Cytotoxicity against mouse primary astrocytes after 5 days by MTT assay [PMID: 22608389]
Astrocyte EC50 51.8 μM Cytotoxicity against Rattus norvegicus Sprague-Dawley (rat) astrocytes after 4 days by cresylecth violet-staining method 10.1007/s00044-010-9356-8
B16-F10 IC50 > 75 μM Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay [PMID: 34795855]
B16-F10 IC50 > 75 μM Cytotoxicity against mouse B16F10 cells after 72 hrs by MTS assay [PMID: 28602669]
B16-F10 IC50 258 μM Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay [PMID: 22809560]
C6 IC50 > 30 μM Antiproliferative activity against rat C6 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay [PMID: 34656900]
C6 EC50 16.5 μM Cytotoxicity against Rattus norvegicus (rat) C6 cells after 4 days by cresylecth violet-staining method 10.1007/s00044-010-9356-8
C6 IC50 34 μM Cytotoxicity against rat C6 cells incubated for 48 hrs by MTT assay [PMID: 23069682]
C6 EC50 60.46 μM Antiproliferative activity against rat C6 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay [PMID: 31978780]

20 records · Scroll to view more

In Vitro Studies

In human U87MG glioblastoma cells cultured with 10% FBS, temozolomide (TMZ) at 800 µM reduced the MTT signal by about 40% at 24–48 h and about 20% at 72 h; 400 µM did not significantly reduce this readout. In separate experiments, 400 and 800 µM TMZ increased caspase-3 activity at 48 h but not significantly at 24 h. TMZ at 800 µM produced a modest increase in PI-positive cells at 72 h, while the 48 h comparison was not significant. MTT, caspase-associated activity and PI positivity are distinct cellular readouts and do not establish a direct molecular target or clinical efficacy. The study used TMZ from Apollo Scientific and does not authenticate Adooq A10575. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Temozolomide MTT response in U87MG cells

Cell-based study · Human U87MG glioblastoma cells (ATCC HTB-14), medium containing 10% FBS [1]

At 800 µM, TMZ significantly reduced the MTT signal at 24, 48 and 72 h; the authors describe about 40% reduction at 24–48 h and about 20% at 72 h. The reduction at 72 h was smaller, not progressively greater. At 400 µM the reduction was not significant in this serum-containing model. MTT measures metabolic reduction and cannot alone distinguish cytostasis, metabolic suppression and cell death.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Vehicle-normalized MTT signal at 800 µM TMZrelative MTT signal Authors report about 40% reduction at 24–48 h and about 20% at 72 h; significant versus vehicle at each time.[1]
MTT response at 400 µM TMZstatistical response No significant reduction versus vehicle at 24, 48 or 72 h in medium with 10% FBS.[1]

Literature-Reported Treatment Conditions

Treatment concentration
400 and 800 µM
Exposure duration
24, 48 and 72 h
Method
TMZ exposure in culture medium; MTT readout normalized to matched vehicle-treated cells.
Vehicle
TMZ dilutions in 1:1 water/DMSO; matched vehicle controls. Methods state a final solvent concentration of 1%; this is not relabeled as 1% DMSO.
Reported limits
Exact numerical means and SEM are not tabulated for the adopted figure panel; approximate reductions are taken from the authors’ prose, not calculated from pixels. Supplier catalog/lot and compound purity are not reported in the checked Chemicals paragraph.
Methods and source locations

Compound reported in the paper: Temozolomide; Compound label in the paper: TMZ

Published temozolomide compound-level findings; the reported material was from Apollo Scientific. No use, equivalence testing or lot certification of Adooq A10575 is established.

Sec3/Par8; Sec4/Par9; Sec5/Par12–15; Sec6/Par16; Sec14/Par25; Sec16/Par28; Fig4A and caption

Vehicle-normalized MTT signal at 800 µM TMZ: MTT reduction assay; mean ± SEM from 5 independent experiments in Figure 4; no numerical digitization. — Sec16/Par28 and Fig4A/caption

MTT response at 400 µM TMZ: MTT reduction assay; five independent experiments in Figure 4. — Sec16/Par28 and Fig4A/caption

Temozolomide-associated caspase-3 activity and PI positivity in U87MG cells

Cell-based study · Human U87MG glioblastoma cells (ATCC HTB-14) [1]

TMZ at 400 and 800 µM increased caspase-3 activity at 48 h, but not significantly at 24 h. At 800 µM, PI positivity increased modestly and significantly at 72 h; the 48 h comparison was not significant. These are cell-death-associated readouts; neither assay establishes a direct molecular target or proves that caspase-3 is required for the response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Caspase-3-associated substrate cleavage after TMZ exposurerelative caspase-3 activity 400 and 800 µM: significant increase at 48 h (P < 0.001 versus vehicle); no significant increase at 24 h.[1]
PI-positive U87MG cells after 800 µM TMZPI-positive cells Modest significant PI positivity at 72 h (P < 0.05 versus vehicle); 48 h comparison not significant. No exact percentage is digitized.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Caspase-3 assay: 400 and 800 µM TMZ; PI assay: 800 µM TMZ
Exposure duration
Caspase-3: 24 and 48 h; PI: 48 and 72 h
Method
Separate culture experiments with fluorogenic caspase-3 substrate cleavage or PI flow cytometry.
Vehicle
TMZ dilutions in 1:1 water/DMSO; matched vehicle controls. Methods state a final solvent concentration of 1%; this is not relabeled as 1% DMSO.
Reported limits
Exact numerical means and SEM for the selected panels are not tabulated. Assay-associated activity/PI positivity does not itself establish causal pathway dependence.
Methods and source locations

Compound reported in the paper: Temozolomide; Compound label in the paper: TMZ

Published temozolomide compound-level findings; the reported material was from Apollo Scientific. No use, equivalence testing or lot certification of Adooq A10575 is established.

Sec3/Par8; Sec4/Par9; Sec5/Par15; Sec8/Par18; Sec9/Par19; Sec14/Par25; Sec17/Par39; Fig5A–B/caption

Caspase-3-associated substrate cleavage after TMZ exposure: Fluorogenic Ac-DEVD-AMC substrate assay, normalized to protein and then vehicle; mean ± SEM from 3–4 independent experiments, with two replicates in methods. — Sec9/Par19; Sec17/Par39; Fig5B/caption

PI-positive U87MG cells after 800 µM TMZ: PI staining and flow cytometry; mean ± SEM from 3–4 independent experiments, two replicates in methods. — Sec8/Par18; Sec17/Par39; Fig5A/caption

In Vivo Studies

In male C57BL/6J Nifdc mice bearing orthotopic luciferase-labeled GL261 tumors, temozolomide (TMZ; 25 mg/kg intraperitoneally once daily for two weeks, beginning one week after implantation) reduced tumor bioluminescence versus vehicle at days 14 and 21. Nectin-4 mRNA, protein and immunohistochemistry scores were higher in TMZ-treated tumor tissues. These concurrent observations do not establish Nectin-4 as a direct TMZ target or show that its induction causes resistance. The selected monotherapy experiment does not establish a survival benefit or human efficacy. [2]

Temozolomide monotherapy in orthotopic GL261 tumors

Animal study · Male C57BL/6J Nifdc mice, 5–6 weeks old at acquisition, with intracranial luciferase-labeled GL261 glioma tumors [2]

In male C57BL/6J Nifdc mice bearing orthotopic luciferase-labeled GL261 tumors, temozolomide (TMZ; 25 mg/kg intraperitoneally once daily for two weeks, beginning one week after implantation) reduced tumor bioluminescence versus vehicle at days 14 and 21. Nectin-4 mRNA, protein and immunohistochemistry scores were higher in TMZ-treated tumor tissues. These concurrent observations do not establish Nectin-4 as a direct TMZ target or show that its induction causes resistance. The selected monotherapy experiment does not establish a survival benefit or human efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor bioluminescence in orthotopic GL261 tumorsbetween-group imaging comparison Lower with TMZ than vehicle on day 14 (P < 0.05) and day 21 (P < 0.01); N = 6 mice per group. No digitized effect size.[2]
Nectin-4 expression in resected brain tumor tissueexpression relative to vehicle Higher Nectin-4 mRNA and protein (each P < 0.001; N = 3 mice/group) and IHC score (P < 0.05; N = 6 mice/group) after TMZ. No exact fold change inferred from pixels.[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once daily
Treatment course
Two weeks, starting one week after tumor implantation
Vehicle
5% DMSO, 30% PEG300, 65% ddH2O
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
TMZ monotherapy
25 mg/kg
Matched vehicle groupLower tumor bioluminescence at days 14 and 21, with higher terminal tumor Nectin-4 mRNA, protein and IHC score versus vehicle.[2]
Vehicle controlReference control groupComparator for tumor bioluminescence and terminal tumor Nectin-4 expression; exact numerical means not tabulated.[2]
TMZ monotherapy
Model: Male C57BL/6J Nifdc mice, 5–6 weeks old at acquisition, with intracranial luciferase-labeled GL261 glioma tumors
Reported limits: Random allocation and imaging-assessment blinding are not stated in checked animal methods. Survival was not an endpoint of this selected Fig2 experiment.
Vehicle control
Model: Male C57BL/6J Nifdc mice, 5–6 weeks old at acquisition, with intracranial luciferase-labeled GL261 glioma tumors
Reported limits: Random allocation and imaging-assessment blinding are not stated in checked animal methods. Survival was not an endpoint of this selected Fig2 experiment.
Methods and source locations

Compound reported in the paper: Temozolomide; Compound label in the paper: TMZ

Published temozolomide evidence using Sigma-Aldrich material; no authentication, equivalence testing or lot certification of Adooq A10575.

s2-1; s2-2; s2-6–s2-10; s3-1 second paragraph; Fig2A–F/caption

Tumor bioluminescence in orthotopic GL261 tumors: IVIS imaging; mean ± SEM; two-way ANOVA with Bonferroni post hoc test. Methods describe absolute radiance, whereas Fig2C labels a relative tumor bioluminescence index; only direction and significance adopted. — s2-8 imaging paragraph; s3-1 second paragraph; Fig2B–C/caption

Nectin-4 expression in resected brain tumor tissue: qRT-PCR, Western blot densitometry with β-actin loading control, and IHC scoring by two blinded pathologists; mean ± SEM; unpaired Student t-tests in Fig2 caption. — s2-6; s2-7; s2-9; s3-1 second paragraph; Fig2D–F/caption

TMZ monotherapy · s2-8 monotherapy paragraph; Fig2A–F/caption

Vehicle control · s2-8 monotherapy paragraph; Fig2A–F/caption

Specifications

Manufacturer Adooq Bioscience
Actions Inducer
CAS Number 85622-93-1
Applications DNA damage inducer
Formula C6H6N6O2
Molecular Weight 194.15
Synonyms Temozolomide; Temodar; Temodal
SMILES
CN1C(=O)N2C=NC(=C2N=N1)C(=O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 37 mg/mL (190.57 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
5% DMSO+30% PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Kucwaj-Brysz K, Podlewska S, Jakubowska K, et al. Spirohydantoin derivatives exert dopamine D2-like receptor-independent cytotoxicity in glioblastoma cells with possible involvement of calpain inhibition Scientific reports (2026). PMID: 41876621 DOI: 10.1038/s41598-026-43014-9 Source material
  2. [2] Zhang XG, Wang H, Song JN. Targeting Nectin-4 sensitizes glioblastoma to temozolomide Frontiers in pharmacology (2026). PMID: 42774203 DOI: 10.3389/fphar.2026.1908590 Source material

Publications

3 publications citing this product

  1. Katarzyna Kucwaj-Brysz, .et al. , Sci Rep, 2026, Mar 24;16(1):14883 PMID: 41876621
  2. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  3. VJ Herbener, .et al. , Biomedicines, 2020, Jun 4;8(6):E151 PMID: 32512726

Added to your cart

View Cart Checkout
Loading...